Organogenesis (NASDAQ:ORGO) Trading 3.9% Higher - Time to Buy?

Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) shot up 3.9% during mid-day trading on Tuesday . The company traded as high as $4.86 and last traded at $4.85. 313,614 shares changed hands during trading, a decline of 72% from the average session volume of 1,124,886 shares. The stock had previously closed at $4.67.

Analyst Ratings Changes

Separately, Morgan Stanley lifted their target price on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th.

Organogenesis Stock Up 6.5 %

The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The company has a 50 day simple moving average of $4.63 and a two-hundred day simple moving average of $3.84. The firm has a market capitalization of $669.79 million, a P/E ratio of -88.00 and a beta of 1.85.

Insider Buying and Selling at Organogenesis

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the transaction, the director now owns 166,879 shares in the company, valued at $851,082.90. The trade was a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 36.90% of the company's stock.

Institutional Trading of Organogenesis

A number of hedge funds and other institutional investors have recently bought and sold shares of ORGO. Victory Capital Management Inc. purchased a new position in Organogenesis during the 1st quarter worth $67,000. CWM LLC lifted its position in shares of Organogenesis by 8.9% during the first quarter. CWM LLC now owns 63,894 shares of the company's stock valued at $276,000 after buying an additional 5,239 shares during the last quarter. Cerity Partners LLC boosted its stake in Organogenesis by 48.2% in the first quarter. Cerity Partners LLC now owns 74,880 shares of the company's stock valued at $323,000 after acquiring an additional 24,362 shares in the last quarter. Palumbo Wealth Management LLC grew its holdings in Organogenesis by 91.5% in the first quarter. Palumbo Wealth Management LLC now owns 38,666 shares of the company's stock worth $167,000 after purchasing an additional 18,476 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its stake in Organogenesis by 10.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company's stock worth $187,000 after buying an additional 4,239 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company's stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.